Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 21, 2008, Pages 5758-5762

  Stevens, Kirk L ^a   Reno, Michael J ^a   Alberti, Jennifer B ^a   Price, Daniel J ^a   Kane Carson, Laurie S ^a   Knick, Victoria B ^a   Shewchuk, Lisa M ^a   Hassell, Anne M ^a   Veal, James M ^a   Davis, Stephen T ^a   Griffin, Robert J ^a   Peel, Michael R ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Cancer; CDK2; CDK4; Cyclin dependant kinase inhibitor; GSK3 ; Pyrazolo 1,5 b pyridazine; VEGFR 2

Indexed keywords

AMINE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; PYRAZOLE DERIVATIVE; PYRIDAZINE DERIVATIVE; VASCULOTROPIN RECEPTOR 2;

ARTICLE; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; IC 50; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

CYCLIN-DEPENDENT KINASE 4; DRUG EVALUATION, PRECLINICAL; DRUG SCREENING ASSAYS, ANTITUMOR; GLYCOGEN SYNTHASE KINASE 3; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PYRIDAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 53949085747     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.09.069     Document Type: Article

References (26)

1. Valentini A., Gravina P., Federici G., and Bernardini S. Cancer Biol. Ther. 62 (2007) 185
2. Bartkova J., Lukas J., Guldberg P., Alsner J., Kirkin A., Zeuthen J., and Bartek J. Cancer Res. 56 (1996) 5475
3. Reissmann P.T., Koga H., Figlin R.A., Holmes E.C., and Slamon D.J. J. Cancer Res. Clin. Oncol. 1252 (1999) 61
4. Gillett C., Fantl V., Smith R., Fisher C., Bartek J., Dickson C., Barnes D., and Peters G. Cancer Res. 547 (1994) 1812
5. Motokura T., and Arnold A. Curr. Opin. Genet. Dev. 31 (1993) 5
6. Arber N., Gammon M.D., Hibshoosh H., Britton J.A., Zhang Y., Schonberg J.B., Roterdam H., Fabian I., Holt P.R., and Weinstein I.B. Hum. Pathol. 309 (1999) 1087
7. Kornmann M., Danenberg K.D., Arber N., Beger H.G., Danenberg P.V., and Korc M. Cancer Res. 5914 (1999) 3505
8. Hosokawa Y., and Andrew A. Genes Chromosom. Cancer 221 (1998) 66
9. Fokkema E., Timens W., de Vries E.G.E., de Jong S., Fidler V., Meijer C., and Groen H.J.M. Lung Cancer 522 (2006) 241
10. Ali A.A., Marcus J.N., Harvey J.P., Roll R., Hodgson C.P., Wildrick D.M., Chakraborty A., and Boman B.M. FASEB J. 7 (1993) 931
11. Pyrazolo[1,5-b]pyridazines have been used as 5HT3-antagonists, Cox 2 inhibitors, and GSK-3β inhibitors. Bondo H.J., Weis J., Suzdak P.D., and Eskesen K. Bioorg. Med. Chem. Lett. 45 (1994) 695
12. Beswick P., Bingham S., Bountra C., Brown T., Browning K., Campbell I., Chessell I., Clayton N., Collins S., Corfield J., Guntrip S., Haslam C., Lambeth P., Lucas F., Mathews N., Murkit G., Naylor A., Pegg N., Pickup E., Player H., Price H., Stevens A., Stratton S., and Wiseman J. Bioorg. Med. Chem. Lett. (2004) 5445
13. Liu L., Zhang L., and Jiang F.-C. Chin. J. Chem. 257 (2007) 892
14. For full experimental details and spectral data on the preparation of pyrazolopyridazines, please see:. Harris P., Jung D., Peel M., Reno M., Rheault T., Stanford J., Stevens K., and Veal J. PCT Int. Appl. 134 (2003) WO 0351886
15. The expression, purification and crystallization of CDK-2/Cyclin A was carried out as previously described. Jeffrey P.D., Russo A.A., Polyak K., Gibbs E., Hurwitz J., Massagué J., and Pavletich N.P. Nature 376 (1995) 313 Crystals were soaked with 50 μM compound for 2 days prior to data collections. The structures were refined to an Rfactor of 21% at 3.0 Å. The PDB deposition codes for the structures are 3EID and XXXX
16. Image generated with PyMol (Delano Scientific).
17. Thomas M.P., McInnes C., and Fischer P.M. J. Med. Chem. 491 (2006) 92
18. Park K.-S., Kim J., Chong Y., and Choo H. Bull. Korean Chem. Soc. 282 (2007) 211
19. Vadivelan S., Sinha B., Irudayam S., and Jagarlapudi S.A.R.P. J. Chem. Inf. Model. 47 (2007) 1526
20. Aronov A., and Murcko M. J. Med. Chem. 47 (2004) 5616
21. Davies T.G., Pratt D.J., Endicott J.A., Johnson L.N., and Noble M.E.M. Pharmacol. Ther. 93 (2002) 125
22. 2, 0.3 mg/mL heparin, 0.1 mg/mL BSA, 1 mM DTT, 2.5 μM ATP, 0.0066 Ci/uL 33P-ATP, and 1.2 μg/mL GSK3β protein were prepared in polystyrene plates. The reactions were started by addition of enzyme to substrate and were terminated by addition of 20 μL of stop solution [0.25 M EDTA, pH 8, 2.5 mM unlabelled ATP]. 195 μL of 1.3 mg/mL StreptAvidin-coated SPA beads in PBS were added and the plates counted in a Packard TopCount (1 min/well) after 10 h.
23. Although we elucidated the demethylation conditions independently, there are examples of using morpholine for demethylations. Goclik V., and Mischnick P. Carbohydr. Res. 338 (2003) 733
24. Bennett G.J., and Lee H.-H. Tetrahedon Lett. 30 51 (1989) 7265
25. Dajani R., Fraser E., Roe S.M., Yeo M., Good V., Thompson V., Dale T.C., and Pearl L.H. EMBO J. 22 (2003) 494
26. The aniline was suggested from. Breault G.A., Ellston R.P.A., Green S., James S.R., Jewsbury P.J., Midgley C.J., Pauptit R.A., Minshull C.A., Tucker J.A., and Pease J.E. Bioorg. Med. Chem. Lett. 1318 (2003) 2961